LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 11, 2017-- LabCorp® (NYSE: LH) announced today that for the period of September 11, 2017 to March 9, 2018 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent

LabCorp Named Among “The World’s Most Innovative Companies” in Forbes’ 2017 Ranking

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 7, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has been named to Forbes’ 2017 ranking of “The World’s Most Innovative Companies.” “Innovation in guiding patient care is what we do at LabCorp, so being recognized as one of the world’s

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 5, 2017-- LabCorp® (NYSE:LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference . LabCorp’s presentation is planned for Tuesday, September 12, 2017 , at 8:35 am (ET) . A live audio webcast will be available via the Company

LabCorp Completes Acquisition of Chiltern

Strengthens LabCorp’s Position as a Global Life Sciences Company with Leading Diagnostics and Drug Development Businesses BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 1, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has completed its previously announced acquisition of Chiltern,

LabCorp’s Acquisition of Chiltern Clears Antitrust Review

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the Federal Trade Commission had granted its request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or

LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer

Caveney is an Influential Thought Leader in Healthcare Financing, Regulatory Initiatives and Value-Based Care Models BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that Dr.

LabCorp Prices $600,000,000 in 3.250% Senior Notes Due 2024 and $600,000,000 in 3.600% Senior Notes Due 2027

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 15, 2017-- LabCorp® (NYSE: LH) announced today that it has priced its offering of $1.2 billion in senior notes. The offering consists of two tranches: $600,000,000 aggregate principal amount of 3.250% Senior Notes due 2024 (the “2024 Notes”) and $600,000,000

LabCorp Announces Proposed Sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 15, 2017-- LabCorp® (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the “Notes”). The Notes will be senior unsecured obligations and will rank equally

LabCorp to Acquire Chiltern for Approximately $1.2 Billion in Cash, Advancing Its Leadership in Drug Development

LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance

Q2 Net revenue of $2.5 billion , up 5% over last year Q2 Diluted EPS of $1.82 , down 7% from last year; Q2 Adjusted EPS of $2.47 , up 5% over last year 2017 Adjusted EPS guidance increased to $9.30 to $9.65 , up 5% to 9% over 2016 BURLINGTON, N.C. --(BUSINESS WIRE)--Jul.